MYNZ MAINZ BIOMED BV

Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023

Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023

Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer. 

BERKELEY, Calif. and MAINZ, Germany, March 01, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, joins advocacy organizations around the world in recognizing Colorectal Cancer Awareness Month in March. Colorectal cancer is the third most common cancer globally, with more than 1.9 million new cases in 2020. This year, Mainz Biomed will be hosting several educational and training events throughout Germany to raise awareness of the importance of early detection.

“We have developed these events to support the colorectal cancer community, as this disease is the third most common cancer globally and the fourth leading cause of cancer death in the US,” said Guido Baechler, Chief Executive Officer of Mainz Biomed. “Our goal is to reduce these statistics and save lives by raising awareness about the simplicity and efficacy of using at-home CRC detection kits, like ColoAlert. Our non-invasive DNA stool test allows people to screen themselves in the comfort of their own home and then receive a follow-up notification from their physician to discuss results and next steps.”

Upcoming Colorectal Cancer Awareness Month Events

Professionals

Training Sessions for gastroenterologists, healthcare providers

Gastro-Update Conference;

#1 Friday and Saturday, March 10-11, 2023 (Time TBD)

Rheingoldhalle; Mainz

#2 Friday and Saturday, March 24-25, 2023 (Time TBD)

Berlin Congress Center; Berlin/

Public

Educational Event for patients, families, caregivers, advocates

Saturday, March 11, 2023 (09:00-16:00)

(Outdoor event venue TBD); Mainz Altstadt

Mainz Biomed invites others to further amplify awareness of CRC by using the #BlueForCRC and #CRCAwareness hashtags on social media and “going blue” on Friday, March 3 by dressing in blue!

For media inquiries, please contact In Europe:

MC Services AG

Anne Hennecke/Caroline Bergmann

20





In the US:

Spectrum Science

Melissa Laverty/Valerie Enes



For investor inquiries, please contact 



EN
01/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MAINZ BIOMED BV

 PRESS RELEASE

DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio

DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio DNA-based Colorectal Cancer Screening as a Home Test BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics diagnostic company specializing in the early detection of cancer, today announced that its test ColoAlert® has been added to the portfolio of DoctorBox, one of Germany’s leading pioneers in digital health. This marks another important milestone in Mainz Biomed’s European growth strategy and highlights the increasing importance of innovati...

 PRESS RELEASE

Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert...

Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America OncoVanguard8 is a leading service provider for innovative healthcare products for insurance companies operating in Peru, Colombia and Ecuador BERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the signing of a Memorandum of Understanding (“MOU”) with OncoVanguard8, a distributor of oncological innovations. The co...

 PRESS RELEASE

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA...

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025 BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in MEDICA 2025, one of the world’s leading healthcare trade shows, taking place from 17–20 November, 2025, in Düsseldorf, Germany. With over 5,000 exhibitors from 70 countries and 80,000 visitors expected, MEDICA continues to serve as a pioneering inte...

 PRESS RELEASE

Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterologi...

Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) BERKELEY, Calif. and MAINZ, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) taking place from 14–15 November, 2025, in Bad Kreuznach, Germany. The annual GARPS conference brings together clinical and s...

 PRESS RELEASE

Mainz Biomed to Attend 2025 Maxim Growth Summit

Mainz Biomed to Attend 2025 Maxim Growth Summit BERKELEY, Calif. and MAINZ, Germany, Oct. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its participation in the upcoming 2025 Maxim Growth Summit, taking place October 22-23, 2025, at The Hard Rock Hotel NYC. The prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. Keynote speakers include Larry Kud...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch